文献速递心律失常心力衰竭与心肌病

地高辛与房颤患者死亡率的关系

Digoxin and Mortality in Patients With Atrial Fibrillation.
PubMed 文献 · J Am Coll Cardiol · 2018-01-01

该研究基于17,897例房颤患者,采用倾向评分校正分析及新用药者匹配对照,评估地高辛使用与死亡的关系。基线使用地高辛与死亡风险无关,但血清地高辛浓度≥1.2 ng/ml者死亡风险增加56%,新使用地高辛者死亡及猝死风险显著升高。

要点

  • 基线地高辛使用与死亡风险无关(调整HR 1.09,95%CI 0.96-1.23)。
  • 血清地高辛浓度≥1.2 ng/ml者死亡风险增加56%(调整HR 1.56)。
  • 新使用地高辛者死亡风险(调整HR 1.78)和猝死风险(调整HR 2.14)显著升高。

核心结论

  • 房颤患者中,地高辛使用者的死亡风险与血清地高辛浓度独立相关,浓度≥1.2 ng/ml时风险最高。
  • 新使用地高辛与房颤患者死亡率升高独立相关,且不受心力衰竭影响。

研究设计与样本

  • 研究纳入17,897例房颤患者,采用倾向评分校正分析评估地高辛使用与死亡的关系。
  • 另在新使用地高辛的患者中,与倾向评分匹配的对照参与者进行比较。
  • 对血清地高辛浓度与死亡的关系进行多变量调整分析。

主要发现

  • 基线时5,824例(32.5%)患者正在使用地高辛。
  • 基线地高辛使用与死亡风险增加无关(调整HR 1.09;95%CI 0.96-1.23;p=0.19)。
  • 血清地高辛浓度≥1.2 ng/ml者较未使用者死亡风险增加56%(调整HR 1.56;95%CI 1.20-2.04)。
  • 血清地高辛浓度每增加0.5 ng/ml,调整后死亡风险增加19%(p=0.0010),且在伴或不伴心力衰竭的患者中结果相似。
  • 与倾向评分匹配的对照相比,新使用地高辛者死亡风险(调整HR 1.78;95%CI 1.37-2.31)和猝死风险(调整HR 2.14;95%CI 1.11-4.12)显著更高。

临床怎么用

  • 使用地高辛的房颤患者应监测血清地高辛浓度,尽量避免浓度≥1.2 ng/ml。
  • 新起始地高辛治疗时需警惕死亡及猝死风险升高,尤其应评估获益与风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Digoxin is widely used in patients with atrial fibrillation (AF). OBJECTIVES: The goal of this paper was to explore whether digoxin use was independently associated with increased mortality in patients with AF and if the association was modified by heart failure and/or serum digoxin concentration. METHODS: The association between digoxin use and mortality was assessed in 17,897 patients by using a propensity score-adjusted analysis and in new digoxin users during the trial versus propensity score-matched control participants. The authors investigated the independent association between serum digoxin concentration and mortality after multivariable adjustment. RESULTS: At baseline, 5,824 (32.5%) patients were receiving digoxin. Baseline digoxin use was not associated with an increased risk of death (adjusted hazard ratio [HR]: 1.09; 95% confidence interval [CI]: 0.96 to 1.23; p = 0.19). However, patients with a serum digoxin concentration ≥1.2 ng/ml had a 56% increased hazard of mortality (adjusted HR: 1.56; 95% CI: 1.20 to 2.04) compared with those not on digoxin. When analyzed as a continuous variable, serum digoxin concentration was associated with a 19% higher adjusted hazard of death for each 0.5-ng/ml increase (p = 0.0010); these results were similar for patients with and without heart failure. Compared with propensity score-matched control participants, the risk of death (adjusted HR: 1.78; 95% CI: 1.37 to 2.31) and sudden death (adjusted HR: 2.14; 95% CI: 1.11 to 4.12) was significantly higher in new digoxin users. CONCLUSIONS: In patients with AF taking digoxin, the risk of death was independently related to serum digoxin concentration and was highest in patients with concentrations ≥1.2 ng/ml. Initiating digoxin was independently associated with higher mortality in patients with AF, regardless of heart failure.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Lopes RD, Rordorf R, De Ferrari GM, et al. Digoxin and Mortality in Patients With Atrial Fibrillation. J Am Coll Cardiol. 2018. PMID: 29519345. doi:10.1016/j.jacc.2017.12.060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。